|
|
Safety a problem for new generation drugs, too
CHICAGO - Nearly a fourth of widely used new-generation biological drugs for several common diseases produce serious side effects that lead to safety warnings soon after they go on the market, the first major study of its kind found.
Source:(AP)
2008-10-21
Therapy helps hard-to-transplant get a new kidney
Nearly one in three patients who need a kidney transplant may never get one because their bodies are abnormally primed to attack a donated organ. Now doctors are trying new ways to outwit the immune system and save more of those so-called "highly sensitized" patients -- often with kidneys donated by living donors, considered the optimal kind.
Nations:U.S. Source:(AP)
2008-10-13
Genentech reports jump in 1Q earnings
Biotechnology giant Genentech Inc. is reporting a jump in its first-quarter profit of 12 percent compared to last year, but sales of its top-selling cancer drug disappointed Wall Street analysts.
2008-04-11
Non-Hodgkin's cancer patients living longer: study
Improved treatments for non-Hodgkin's lymphoma helped patients live longer in the United States, researchers said on Monday.
2008-03-10
Genentech shares fall as Avastin disappoints
Biotechnology company Genentech Inc (DNA.N) said on Monday its fourth-quarter profit rose 6.4 percent, but sales of several drugs, including blockbuster cancer drug Avastin, fell short of investor expectations, sending the company's shares lower.
Nations:U.S.
2008-01-14
|